SMN2 and proximal spinal muscular atrophy: The major challenges of SMA screening tests are related to the DNA quality and quantity and cross-reaction of SMN1 with SMN2. This seems to be successfully circumvented through different DNA extraction methods and LNA primers/probes and/or well-established cutoffs [22].